Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
- Marvin S. Swartz(corresponding author),
- Diana O. Perkins,
- T. Scott Stroup,
- ,
- Jennifer M. Nieri,
- David C. Haak
- Duke University,
- University of North Carolina at Chapel Hill,
Scholary Output:
Contribution to journal
Review article
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 33-43 (11 pages)Journal (Volume, Issue Number)
Schizophrenia Bulletin (Volume 29, Issue 1)Publication milestones
- Published - 2003
Publication status
Published - 2003
ISSN
0586-7614Publication IDs
- Scopus: 0037771503
- PubMed: 12908659
Publication metrics
Metrics
SciVal
citations
90
SciVal
FWCI
2.49
SciVal
Author count
6
SciVal
Paper percentile
93
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
103
Captures
104
